Loading clinical trials...
Loading clinical trials...
Post-marketing Clinical Trial of Pegasys® 180μg for Subcutaneous Injection in Patients With Chronic Hepatitis C. General Clinical Study in Interferon (IFN)-Treated and IFN-untreated Chronic Hepatitis C Patients, Except for Those Infected With High Viral Load of Genotype 1b
The purpose of this study is to investigate the efficacy and safety of Pegasys® 180μg for subcutaneous (s.c.) injection in interferon (IFN)-treated or IFN-untreated chronic hepatitis C patients except for those infected with genotype 1b of hepatitis C virus (HCV) and a high viral load (≥ 100 KIU/mL). In addition, this study will explore the efficacy and safety of Pegasys® 180μg for s.c. injection given at 2 different periods between 24 and 48 weeks in IFN-untreated chronic hepatitis C patients.
Age
20 - No limit years
Sex
ALL
Healthy Volunteers
No
Kyusyu Region
Fukuoka, Japan
Chugoku Region
Okayama, Japan
Kinki Region
Osaka, Japan
Hokkaido Region
Sapporo, Japan
Kanto Region
Tokyo, Japan
Tokai Region
Yamanashi, Japan
Start Date
October 1, 2005
Primary Completion Date
July 1, 2010
Completion Date
July 1, 2010
Last Updated
November 17, 2010
108
ACTUAL participants
Pegasys®
DRUG
Pegasys®
DRUG
Lead Sponsor
Chugai Pharmaceutical
NCT00199719
NCT06922643
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03612973